Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

Trial Profile

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INT 230-6 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Chordoma; Colon cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Pancreatic cancer; Skin cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Intensity Therapeutics
  • Most Recent Events

    • 31 Oct 2019 According to an Intensity Therapeutics media release, the first patient has been dosed with a combination of INT2306 and Keytruda (pembrolizumab)
    • 22 Oct 2019 According to an Intensity Therapeutics media release, data from this trial will be presented at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting, taking place November 6-10, 2019, in National Harbor, MD.
    • 05 Sep 2019 Planned number of patients changed from 60 to 110.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top